Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
May 10, 2022 02:17 PM EDT
R&D

Just months af­ter its first FDA ap­proval, Idor­sia dumps binge-eat­ing drug can­di­date af­ter PhII fail

Paul Schloesser

Associate Editor

Idor­sia got a po­ten­tial block­buster drug ap­proval back in Jan­u­ary — the first ap­proval since the small Swiss biotech spun out in 2017. And while a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times